InMed Stock Based Compensation from 2010 to 2025
| INM Stock | USD 2.65 0.20 7.02% |
Stock Based Compensation | First Reported 2009-03-31 | Previous Quarter 29 K | Current Value 23.2 K | Quarterly Volatility 276.8 K |
Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 284.9 K, Interest Expense of 153.3 K or Selling General Administrative of 6.3 B, as well as many indicators such as Price To Sales Ratio of 9.11, Dividend Yield of 0.0 or PTB Ratio of 4.55. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
InMed | Stock Based Compensation |
Latest InMed Pharmaceuticals' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of InMed Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. InMed Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
InMed Stock Based Compensation Regression Statistics
| Arithmetic Mean | 884,036 | |
| Geometric Mean | 549,684 | |
| Coefficient Of Variation | 97.23 | |
| Mean Deviation | 620,906 | |
| Median | 666,832 | |
| Standard Deviation | 859,508 | |
| Sample Variance | 738.8B | |
| Range | 3M | |
| R-Value | (0.19) | |
| Mean Square Error | 763.2B | |
| R-Squared | 0.04 | |
| Significance | 0.48 | |
| Slope | (34,159) | |
| Total Sum of Squares | 11.1T |
InMed Stock Based Compensation History
Other Fundumenentals of InMed Pharmaceuticals
InMed Pharmaceuticals Stock Based Compensation component correlations
Click cells to compare fundamentals
About InMed Pharmaceuticals Financial Statements
InMed Pharmaceuticals investors utilize fundamental indicators, such as Stock Based Compensation, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 123.9 K | 117.7 K | |
| Stock Based Compensation To Revenue | 0.03 | 0.03 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of InMed Pharmaceuticals Correlation against competitors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.26) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.